what is tesamorelin?
the only FDA-approved GHRH analog -- and the honest case for a drug whose label says HIV-associated lipodystrophy
an FDA-approved GHRH analog with a specific medical indication
Tesamorelin -- branded Egrifta -- is a synthetic peptide drug approved by the FDA in November 2010 for one specific use: reducing excess abdominal fat in HIV-infected patients with lipodystrophy, a disfiguring metabolic complication of older antiretroviral regimens. As of 2026, it is still the only FDA-approved GHRH analog on the US market (FDA Egrifta label; Falutz et al. 2007).
That indication is narrow, and it shapes everything else about this course. Tesamorelin sits in a different evidence tier than sermorelin or CJC-1295 -- it has Phase 3 randomized-controlled-trial data behind it, in the population it was approved for. But it is also not a generic anti-aging tool, not a GLP-1 alternative, and not a "natural alternative to growth hormone." The honest story is more interesting than any of those marketing positions, and that is what the next ten units unpack (Falutz et al. 2010; Stanley et al. 2014).
a stabilized GHRH(1-44)
why tesamorelin keeps all 44 residues of native GHRH instead of trimming to 29, and the one chemical cap that makes the molecule survive in plasma.
the parent molecule is the full native hormone
Tesamorelin's parent molecule is full-length human growth hormone-releasing hormone (GHRH(1-44)). Sermorelin, by contrast, is just the first 29 residues. Both molecules bind the same receptor with similar affinity -- the receptor pharmacology is essentially identical (Mayo et al. 1995; Prakash and Goa 1999). What tesamorelin gets from keeping the full backbone is not a different receptor signal; it is a different shape for the modification chemistry to work on.
one chemical change at the N-terminus
The single chemical difference between tesamorelin and native GHRH(1-44) is a trans-3-hexenoyl group -- a small six-carbon acyl chain with one double bond -- covalently attached to the alpha-amine of Tyr1, the very first residue. That tiny cap sterically blocks DPP-IV, the serum protease that would otherwise cleave the molecule at the Ala2-Asp3 bond within minutes (Falutz et al. 2007).
The result is a peptide with the same receptor pharmacology as native GHRH and a plasma half-life of roughly 26-38 minutes instead of the ~12 minutes that sermorelin and native GHRH share (Gonzalez-Sales et al. 2015).
key terms
definitions for the technical words that show up across this course. tap to expand.
interactive: GHRH(1-44) with the trans-3-hexenoyl cap
tap any residue to see what its side chain contributes and where the trans-3-hexenoyl cap sits on Tyr1. the interactive locks in the same anchors the paid units expand on, so use it as a study guide while you work through the course.
tap the trans-3-hexenoyl cap or any residue of GHRH(1-44) to see what it does and how the cap blocks DPP-IV cleavage
the only FDA-approved GHRH analog
why "FDA-approved" actually means something concrete here -- and what indication that approval is tied to.
approved November 2010 by Theratechnologies
The FDA approved Egrifta (tesamorelin for injection) in November 2010 as the first -- and still only -- drug specifically indicated for "the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy" (FDA Egrifta label). The sponsor was the Canadian biotech Theratechnologies, which had developed the molecule under the codename TH9507.
two reformulations followed
Adherence to the original Egrifta was limited by a two-vial reconstitution workflow and refrigerated storage. Egrifta SV, a sucrose-stabilized formulation, was approved later to eliminate the cold-chain step. Egrifta WR, a once-daily 1 mg/0.25 mL pre-filled pen with extended room-temperature stability, is the most recent formulation. The molecule is identical across all three; only the formulation chemistry changed.
no other GHRH analog has FDA approval today
Sermorelin lost its branded product (Geref) in 2008 for commercial -- not safety -- reasons (Federal Register 2013). CJC-1295 has never been approved. Modified GRF(1-29) and ipamorelin are research-only or compounded. Tesamorelin's regulatory uniqueness is real, and it is the single most important fact for evaluating any claim about it.
FDA Egrifta prescribing information
"EGRIFTA is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy."
The labeled indication is narrow and specific. Anything outside it is off-label (FDA Egrifta label).
the honest positioning
what tesamorelin is for, what it is not for, and the difference that actually matters.
it is for a specific medical condition
Tesamorelin was developed for one population: HIV-infected adults with the disfiguring central fat accumulation that older antiretroviral regimens caused. That is the population in which the Phase 3 trials were run, the population the FDA approved it for, and the population in which the long-term safety data exists (Falutz et al. 2007; Falutz et al. 2010).
community use exists outside that population
A real off-label community use of tesamorelin exists in non-HIV adults pursuing visceral fat reduction or general "metabolic optimization." This course will be direct: the controlled evidence for that use does not exist at scale. The biological plausibility is real -- the receptor pharmacology and downstream IGF-1 axis are the same regardless of HIV status -- but plausibility is not RCT data.
HIV-associated lipodystrophy
2 mg/day SubQ tesamorelin in HIV-infected adults with excess abdominal fat. ~15% VAT reduction at 26 weeks, sustained through 52 weeks, durable in the modern integrase-inhibitor era (Falutz 2007; Russo 2024).
HIV-associated NAFLD
Stanley 2014 JAMA and Stanley 2019 Lancet HIV established meaningful hepatic fat reduction in HIV-infected adults. Off-label because the FDA has not extended the label, not because the evidence is thin (Stanley 2014; Stanley 2019).
non-HIV visceral fat
No large RCTs exist in non-HIV centrally obese adults. Biological plausibility is reasonable. Community use is widespread. The honest framing is extrapolation, not evidence.
"anti-aging" / GH-replacement
Tesamorelin is not a generic anti-aging tool, not a replacement for rhGH in adult GHD, and not a GLP-1 agonist analog for weight loss. Marketing it as any of these is wrong (Sigalos and Pastuszak 2018).
why this framing matters
The off-label community has every right to exist. What it should not do is borrow the credibility of the Phase 3 HIV-lipodystrophy data without acknowledging the population mismatch. A course on tesamorelin should be honest about both halves of that picture, and that is the approach the next nine units take.
honest evidence ceiling
what is RCT-grade, what is suggestive, and where the controlled evidence simply does not exist.
HIV-associated lipodystrophy
Two Phase 3 RCTs in the on-label population, supported by 52-week safety extension and modern-era replication.
- Falutz 2007 NEJM Phase 3 pivotal trial (n=412): ~15.2% VAT reduction at 26 weeks vs +5% placebo.
- Falutz 2010 JCEM pooled analysis with safety extension confirmed durable VAT response through 52 weeks.
- Russo 2024 AIDS re-examined efficacy in the modern integrase-inhibitor era and reported preserved response.
HIV-associated NAFLD
Two solid RCTs of hepatic fat reduction in HIV-infected adults. Not in the FDA label, but the evidence quality is high.
- Stanley 2014 JAMA single-center RCT: ~32% relative reduction in hepatic fat fraction by MRS at 12 months.
- Stanley 2019 Lancet HIV multicentre RCT confirmed and extended with biopsy substudy.
- Fourman 2017 linked visceral fat reduction to improved liver enzyme profiles in HIV.
muscle quality and cognition
Phase 3 imaging re-analyses and small investigator-initiated cognitive trials. Hypothesis-generating, not clinical recommendation.
- Adrian 2019 re-analysis: reduced intramuscular fat and increased thigh muscle area in HIV-infected adults on tesamorelin.
- Baker 2012 Arch Neurol: improved executive function in MCI and healthy older adults with 1 mg nightly for 20 weeks.
- Friedman 2013 JAMA Neurol: elevated cortical GABA by MRS in the Baker 2012 cohort.
non-HIV adults at scale
As of 2026, none of the following exist.
- no large RCT of tesamorelin in non-HIV centrally obese adults.
- no head-to-head trial against GLP-1 agonists for visceral fat reduction.
- no Phase 3 program in primary (non-HIV) NAFLD or NASH.
- no long-term safety dataset in healthy adults using compounded tesamorelin off-label.
what you will learn
where this course goes from here.
The next ten units take this overview and go much deeper. The chemistry units dissect the GHRH(1-44) backbone and the trans-3-hexenoyl stabilization. The mechanism units walk through pulsatile GH biology and how visceral fat reduction follows. The marquee evidence units cover the Falutz Phase 3 program and the Stanley NAFLD trials. The comparison unit puts tesamorelin next to sermorelin, CJC-1295, ipamorelin, and rhGH. The closing unit is honest about regulatory status and what users actually pay.
-
02
GHRH(1-44) biology and the receptor
the native GHRH(1-44) sequence, the GHRHR class B GPCR on pituitary somatotropes, and why tesamorelin keeps all 44 residues instead of trimming to 29.
-
03
stabilization: the trans-3-hexenoyl cap
the DPP-IV problem that limits native GHRH and sermorelin to ~12 minutes, the chemical mechanism of the N-terminal acyl cap, and the 26-38 minute half-life that results.
-
04
pulsatility, feedback, and IGF-1
why preserved pulsatility matters more than total GH dose, how somatostatin and IGF-1 feedback loops stay intact, and the mechanism linking IGF-1 to visceral fat reduction.
-
05
HIV-associated lipodystrophy
the on-label population in detail -- older antiretroviral regimens, the visceral fat phenotype, the unmet need that drove tesamorelin development, and how the modern integrase-inhibitor era changes who is treated.
-
06
the Falutz Phase 3 program
the marquee evidence unit. Falutz 2007 NEJM pivotal trial, Falutz 2010 JCEM pooled analysis with 52-week safety extension, and the 2024 Russo INSTI-era confirmation.
-
07
NAFLD: Stanley 2014 and 2019
Stanley 2014 JAMA hepatic fat trial, Stanley 2019 Lancet HIV multicentre trial with biopsy substudy, and why HIV-NAFLD use stays off-label despite high-quality RCT evidence.
-
08
dosing, administration, and monitoring
the labeled 2 mg SubQ daily regimen, the formulation evolution from Egrifta to SV to WR, IGF-1 and glycemic monitoring guardrails, and the adverse event profile.
-
09
versus sermorelin, CJC-1295, ipamorelin, rhGH
the analog landscape side by side -- mechanism, half-life, FDA status, clinical evidence, and where tesamorelin actually fits in the GH-axis cluster.
-
10
regulatory status and access economics
FDA approval history, the ~$25K/year branded price wall, the compounded tesamorelin landscape and its caveats, WADA prohibition, and what users actually pay.
-
11
final exam and certification
comprehensive exam covering all ten prior units. pass at 80% and earn a Tesamorelin Specialist certificate.
By the end you should be able to read a paper, a vendor page, or a Reddit thread about tesamorelin and immediately tell which claims trace to the Phase 3 HIV trials, which are reasonable extrapolations, and which are pure marketing.
Knowledge Check
confirm the tesamorelin identity, the FDA framing, the half-life delta, and the evidence-ceiling tiers before moving deeper.
Practice
reinforce the anchors that carry through the rest of the course.